Management Team
Professor Cedric Yu
Chief Executive Officer
Professor Cedric Yu, DSc, FAAPM has served as CEO of Xcision since 2011. Dr. Yu is responsible for establishing the company’s strategic priorities, growing the leadership team, providing thought leadership on new product development and fundraising. Dr. Yu has a proven track record as a visionary developer of medical technologies that have transformed the radiotherapy industry. Six of Dr. Yu’s patents are currently licensed by radiotherapy companies, including Varian, Siemens, Elekta and Prowess. Products sold using one such patent for intensity modulated arc therapy, current known as VMAT or Rapid Arc, are used daily in the thousands of radiation oncology departments across the world and have generated billions of dollars in sales of hardware and software systems.
Dr. Yu was the endowed Carl M. Mansfield Professor in Radiation Oncology at the University of Maryland and has a 20-year track record of successful translational research. He has periodically worked with the medical device industry and has prepared FDA 510(k) submissions for five medical devices, all of which were cleared within 120 days. He has published more than 100 peer-reviewed articles in scientific journals, more than 150 published abstracts and seven book chapters and reviews. He holds 22 patents on many inventions in this field.
Peter Maton
Vice President of Engineering
Peter Maton joined Xcision in 2011 as VP of Engineering. In this capacity, he oversees the strategic direction and all technical aspects of development and service operations for the GammaPod product. Mr. Maton has more than 35 years of management experience in the development of cancer care technology and a successful track record of bringing high quality, safe and reliable products to the market.
Michelle Crawley
President
Michelle Crawley joined Xcision in 2012 as VP of Operations. In 2020 she assumed responsibility for the regulatory and quality assurance activities. In 2022, she was promoted to President and is now responsible for developing and implementing the strategy and day-to-day functioning of the organization, for sales and operations outside of mainland China.
Ms. Crawley joined the company after over 13 years at Elekta where she served as the Director of North American Operations, Director of Integration and lastly as the VP of Contracts and Sales Support during the company’s largest growth period to date. Prior to her engagement with Elekta, she served on the Space Shuttle program for over 13 years in a variety of technical project management and quality assurance roles.
Marrine Shen
Financial Controller and Head of Operations
Marrine Shen joined Xcision in 2016 as Financial Controller. In this role, she is responsible for the full cycle of Accounting and Finance, which includes establishing financial policies and procedures, generating financial reports and oversight of auditing and tax filing work by external accounting firms. In 2023, Marrine assumed responsibility for the purchasing, operations, logistics and supplier management procedures. Ms. Shen brings more than 15 years of regulated industry experience, most recently as an Accounting Manager for three years at Merchant Link, a joint venture of J.P. Morgan Chase & Co. and First Data.
Tammy Lavery
Regulatory Affairs and Quality Assurance
In her role over Regulatory Affairs and Quality Assurance, Tammy is responsible for all aspects of the company’s regulatory strategy and quality assurance requirements. Tammy’s activities include planning and coordination of regulatory submissions to support business objectives, communications with regulatory authorities and ongoing implementation, monitoring and improvement of the Quality Management System to assure regulatory compliance. In joining the Xcision team, Tammy brings over 20 years of medical device regulatory affairs and quality assurance experience.